MTNB - Earnings call transcript Q2 2019 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Matinas BioPharma Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Peter Buzzel [ph] of Westwood, Investor Relations from Matinas BioPharma. Peter. ahead, go Please

Unidentified Company Representative

Good BioPharma and call. second Kevin. joining you the Matinas quarter morning you, thank everyone for Thank results conference

this section. along a quarter issued the Matinas release morning with under on Earlier second the website our Investors is press available XXXX business with release results BioPharma updates. The financial we

Scientific Matkovits, Office; Ferguson, Chief Chief Medical Joining me are and today Raphael Terry call Officer; Officer; Jerry Jabbour, Dr. Dr. Chief Dr. Terry Chief Kucinski, on the our Development and Chief Financial Executive Keith Officer; Mannino, Officer.

like At I management's remind time, or remarks uncertainties. These this that beliefs, involve made hopes, this would projections state to may statements our future. the and forward-looking call listeners of expectations during risks intentions,

to federal on results of Harbor Forward-looking statements the and current on Safe securities are based These this the forward-looking Matinas statements BioPharma's differ materially. actual expectations pursuant provisions could call laws. made are

not statements. reliance result, undue on a place forward-looking you any As should

Some contemplated the results of the Matinas the factors the of materially BioPharma available discussed Commission. documents and in filed section such the Securities periodic on are statements by from Investors the in reports These with website actual website. are differ to Exchange forward-looking and company's that SEC's could cause those

on company's are the we call. website, which morning's call. summarize can that of also These today's that note, of will some Please key slides Investors the be slides providing accompany discussed updates section this found the in

section. website, archive in an Finally, this Relations be the call of also to will the Investor posted company's

will question-and-answer prepared call Following for we remarks, the up company's the open session.

over to call now turn will the I Jerry.

Jerry Jabbour

today quarter we time welcome provide everyone. business results discuss update. to Good our morning join for Thanks you, second and taking Peter. a and XXXX the as us Thank

XX up made important to our company and exciting set candidates our progress of In now next QX, for on XX an months. objectives product number that key a Matinas

of development our necessary and continued have into products. product further MATXXXX, supply to intermediate on drug We lead and candidate, securing focus final on advancing

are creating busy be what to product. highly a a believe value for set period differentiated omega-X begin and very We prescription-only will this and we promising

We of amphotericin lead study and a important unmet an candidate phase area have oral drug towards LNC also MATXXXX, interesting our very our medical of of cryptococcal need. initiation extremely X moving been formulation and busy B, meningitis, platform significant

As we initiate through studies, momentum expect of build the XXXX this we and and second half conduct XXXX. continue to these throughout on to

we we specifically programs. multiple activity underway We flow positioned what will believe with benefit are believe the news period and getting well the side-effects begin I from of could cost. at affordable omega-X space, potentially new be that studies which plagued tens also this continued cardiovascular benefit the of patients to without clinical some drugs two of an our with a compelling of traditionally our increasing of will millions across medicines of in class have emergence

who our will I We'll call off Matkovits, will further both, and in morning overview level discuss provide MATXXXX. to a to cryptococcal over comments upcoming then This Dr. Ferguson discuss few to Dr. turn an the MATXXXX on MATXXXX. things study provide meningitis. Terry Then hand MATXXXX and of Terry high

Finally, second Keith our results. provide of a financial overview Kucinski quarter will brief

of bridging the an larger in This we a approved end-life omega-X continue data development treatment of am on the that initiate We adaptive is the required and are on to differentiate field this in world the and I class we to ahead comparative generating back conditions. ahead the on seen and bioavailability products. emerge with study leading put for schedule pleased to MATXXXX, prescription-only time toxicology this of we the Regarding prescription-only on-track careful been of an data focused is risk. MATXXXX. extremely schedule Because clinical our into and focused from exciting report this study of hypertriglyceridemia remain have cardiovascular to still could MATXXXX completed reducing place believe omega-X's clinic, evolving, product cardiovascular portion strategy benefits for guiding into metabolic

this patients protocol Importantly, PD considered the study generated and XXXX. we data which PK on top line could timing strength a and advance Vascepa, AstraZeneca potential early anticipate in are in to market. have QX beginning data finalized data positive line $XX to second our drug already This and study best-in-class dosing in is This are be the of the patients Vascepa builds from versus currently ideal scheduled the billion-plus pre-screened Top trial. begin the anticipated against study XXXX. head-to-head of head-to-head announcement and from in

further candidate unmet was the upon This with we recent based medical product drug MATXXXX recently of meningitis. the that now disease critical program platform. fast forward NIH-funded moving from lead where a with positive with Lipid fourth on the Phase infectious underscored MATXXXX; with important status in our could feedback track our focused had for the received Nano-Crystal MATXXXX This We development with this FDA and receipt cryptococcal meningitis, our delivery study. need our Turning to cryptococcal feedback of EnACT demonstrated qualified our designation FDA for meeting our X/X address. treatment

label study Health, of as the preparing later the Matkovits of study on Institutes will this drawn patients the the the grant more objectives, to funded a call. of a that in provide fully Known National and study. details for which X/X a bit be design, study, cohort Dr. study with pursuant will conclusions may from infected MATXXXX the study course the the cryptococcal from over suffering meningitis. treatment are initiate be to sequential conducted open EnACT study We HIV Phase combined

like Dr. would Terry our some the now on in turn Ferguson cardiovascular call to program, developments to over provide details on commentary the additional to I and MATXXXX space.

Terry Ferguson

good morning and Jerry, Thanks everyone.

only we've where to likely next patients also currently not advance they of the MATXXXX over the evolve with we years. environments to hypertriglyceridemia. but to how careful and the previous on calls, involves few pathway regulatory clinical outlined are As consideration program This continue stand treat

elevated about plan data builds strategy be of providing and Vascepa. of it. on As begin patients MATXXXX similar experience addition between versus prior month patients reduce we're of a next the randomized the enroll patients XX Vascepa number for head-to-head milligrams or in MATXXX, to currently MATXXXX longer to The deciliter, for design additional pre-screening treated We and milligrams in approximately regulatory earlier, and in Jerry discussed early study period. to patients a first the XXX either we in begin with larger the initiating XXX quarter included for We'll Vascepa. excited head-to-head plan are per studies an triglycerides versus our in those XXXX. to enrollment undertaking We support study to of

be XX Each with a one Each food. receive capsules days XX of patient will treatment. initial The daily therapy month. two treatment for washout then of study be will an other approximately the days phase patient to additional with crossed period of over twice will drugs

be versus line Our on in, early triglycerides, MATXXXX and QX XXXX, observations in have the to greater Based we confirm look Apo top data patient QX also VLDL-C, and expected bioavailability expectation that we of PCSKX. the will Vascepa, is available C-X non-HDL-C, of an reducing total first the will prior study in from XXXX. cholesterol, anticipate in

contributor evolution included will trial drugs of enthusiasm create concluded patient drugs to prescription therapy continues generally, has the will positive the ADA The is that Vascepa than indicators this the most acceptance for the an reduce even trial, the updated [ph] other of positive. These strength development omega-X important Vascepa be cost-effective More prescription omega-X build. population all the be risk expectation for recently patients. that momentum I it, of a The is recent and done guidelines in solution growing to and therapies. also are for omega-X an also in emerging including is believe of ICER which that prescription-only class being MATXXXX. similar in group it's positive non-profit higher

of become as we to available. as MATXXXX we short relatively made additional look and proud and studies a the providing of progress I'm data forward with from progress these have updates these trials time period in

over turn Matkovits. the With Theresa that, to I'll call

Theresa Matkovits

Terry Thanks, patients will meningitis. our cryptococcal study few everyone. MATXXXX with and provide highlights discuss I and a on morning, good upcoming key in

recent the treatment interaction of most qualified now our meningitis Health, disease our most with cryptococcal With the of status, drug amphotericin supported by an poor is been and fungicidal This of toxicity historically and and our following drug the of of a profile. indications. and IV-only Institutes pre-clinical both, regulatory administered on activity fast-track is in overall target tolerability has support in the with designation June. we an with FDA, studies formulation time but variety administered MATXXXX multiple recent pathway, orally supporting late National focused some in infectious B, are clinical for development a product

high Cryptococcal an fungal with of central meningitis is system and is a severe of unmet medical the infection treatment poor life-threatening currently needs nervous alternatives. area

study for period therapy and extended The limited is treatment. Encochleated Trial was goal amphotericin patient course which patients. for being developed designed most in involves safety. Our sick important the fluconazole Oral very with to these explore maintenance maintenance treatment MATXXXX followed protocol for stands standard-of-care an for to the use study both, Amphotericin toxicity, of Cryptococcal it's by very due EnACT of the with induction Current IV a renal Meningitis

treatment patient patients the options. than ineffectiveness typically current population, treated this more underscoring the of die, XX% Within of

multiple-dose days involving dose longer in distinct and a parts, split maximum determine a with of the infection, months. We X, additional HIV-positive patients X-arm additional for phase dose term have tolerated in over single next dose, tolerability. designed study the part this progress by to XA Part several and portion though design meaning commence the determine be will receiving study followed portion XA This X protocol the two to ascending of September in X volunteers without X from fungal safety to healthy, the into

standard approximately with the the signal of between the the will positive with be as in patients of cohort compared optimal HIV Once tolerability XXX There enrollment X X of stage evaluate phase scheduled safety. safety, a DMC, for patients meningitis Committee with and for terms been Monitoring for independent XX-weeks safety trial the of sequential open-label MATXXXX the Phase from in B. to viewed and efficacy drugs among approved or stages pauses reviews portion XXXX. next amphotericin QX an will Data Phase both, cohort infected to around IV-administered perspective patient of DMC by has dose commence cryptococcal progression study and is efficacy or X selected

to this in the cohort maintenance followed be each after occur will induction will therapy next treatment review followed XX next induction the to will followed B of phase X X X by Cohort XX of point, the phase. patients cohort XX or the by the days days balance the induction of remaining portion XX-week consist of of IV induction of days. Consolidation the At administration IV will days will move a data which begin phase X by phase, for the third Upon XX B commence patients the period. or patients. will DMC phase made amphotericin the MATXXXX. X by for days patients with continue be MATXXXX days with overall then of two begin for X the the amphotericin in amphotericin Cohort induction MATXXXX of administered where for will IV of decision

safety the The endpoints cohort survival Multiple fungal the study the survival for MATXXXX induction fluid. in secondary clearance of multiple period. is this hospital-free of will fourth include endpoint and of receive in and primary XX-week the the XX Finally, patients cerebrospinal XX-day markers. entirety rate

important are with believe which pleased while patient-first the on up of design an Institutes our oral the generation this which with nature allowing University fungal the properly a for design requires study and patient safety of crossing We blood-brain study impact National deadly have Minnesota collaborative work of barrier We and of can focuses therapy. data infection MATXXXX we come the the with Health. the of on the have demonstrating with this

highly cryptococcal and is This of both meningitis. indications believe and could but the an and design we unusual position study induction promising maintenance challenging, treatment for which MATXXXX

in progression will desired from in results full that a to MATXXXX the we cohort impact. available from having positively this sign this viewed cohort and study be XXXX, may be study is While likely that believe the

We will to during as plan comment calls. our appropriate quarterly update

call the a for turn of overview second I Keith quarter financial now brief to our results. will over

Keith Kucinski

attributable $X.XX reported to a or loss diluted share, This Thanks, common shareholders hello, loss shareholders $X.X essentially or to share per morning common million everyone. $X.X net and unchanged million same we $X.XX a and of the attributable per year. quarter the basic from basic last diluted and net for Terry of

expenses of million The and with increase XXXX. quarter compared $X.X clinical quarter administrative with General to company's XXXX; second compared MATXXXX. quarter public net Research last compared million. million G&A $X.X million year's equivalents primarily in of million and at development second completed the the to higher the costs same in $X R&D and $X.X cash offerings cash $XX.X to year-end increase this approximately We proceeds expenses of expenses due million were were development $XX.X associated of ended includes million to $XX.X in March. from is

continue is Based to on that we quarter cash-on-hand operations of projections, into believe to XXXX. current our fund the sufficient first

I'll the for now over Jerry call some back remarks. turn to closing

Jerry Jabbour

Keith. Thanks,

today some our provide to to Just key following update. the group takeaways

set our the in comparative MATXXXX, initiate For to coming trial we're PK weeks.

pre-screening study to patient head-to-head for our Vascepa. We set are also begin against

by recent in by a invasive of QX QX XXXX QIDP top Finally, set Institutes have meningitis. funded study, updates meeting fast-track of and course the the and cryptococcal XXXX. our FDA expect fungal over to XXXX XXXX the can commence move approval portion we data PK with is treatment deadly designations important in a quarter impact we'll MATXXXX thereafter MATXXXX as short for Health, study expected and to On and fully dosing National in the infection fourth head-to-head of begin positive and study from of cohort-to-cohort the the we supported meningitis, EnACT following XXXX that time provide of in to of study that the on initiate of cryptococcal MATXXXX line the is expected demonstrating this which are in to

we exciting to extremely The continuing believe months progress. milestones company. of and an be we value XX the thank for In us We following along to creating next for and full summary, you events. update look XX shareholders time to it's valued will forward on our with our

begin will With can back the turn our it so to question-and-answer over session. we that, I operator

Operator

from first Bert Instructions] BTIG. [Operator with today you. Hazlett Our come question Thank is

Your line is now live.

Robert Hazlett

of previously the but think in you've twice I on you talk endpoints additional Congratulations you've discussed a triglycerides about would have once study couple beyond a for? now And you. Thank already important have crossover seen with -- couple days could What's other you be I that secondary XX I important that that ones additional this MATXXXX? progress. well. Terry, looking the questions. you might as of or the study,

Terry Ferguson

Apo addition are opportunity the bioavailability, are have. validate already C-X, comparing and more build don't Thanks MATXXXX are of lipid exploratory I would markers for on versus head-to-head markers increase. opportunities that was the that answer that to we levels think the of validate observations a that variety prior to a question. deeper be the other information hope to at looking to that Vascepa lipid but PCSKX; There in the to and the The non-HDL, observations question be LDL reinforce I Bert? there of into prior is shown Does probe an study. what the head-to-head nature -- study we to I markers, think And going important highlighted in the and the

Robert Hazlett

clear. That's That does, you. thank very

LNC first EnACT it's of forward the -- study; and rapidly. that the moving encouraging really that shifting to is all, So

a EnACT, for additional in success XXXX? be there with you Assuming consideration label would expect to broadening

Theresa Matkovits

Yes. Thank the you question. for

and Our with expand the conversation allow indications leverage XXXVX expect further we expectation to do MATXXXX. [ph] us agency, for to pathway the in potential to

leverage allow of products started the amphotericin data already the with We generated on strategy safety with already the have many bridging to that a will FDA market. us and discussions years already

expectation just absolutely expand meningitis. reach cryptococcal as our you've to So is our indicated beyond

Robert Hazlett

well. Thank you, forward to look that as

business have on been And there? question LNC; that focus still Jerry, with events potential is there underway? upcoming Just licensing on and that; potential development a is additional some there quick

Jerry Jabbour

questions. the Yes, thanks Bert for

approaches the this products then we formulation a the and and ViiV, those obviously clinic, in coming we're outlined focused collaborations foremost, with the on any and we've and And have oligo that And much ongoing. look with that specifically, have products advancing quarters. development say call that's but ViiV to year. the we in very those Healthcare of this on of kind not Healthcare respect to and less antiviral advancing that one differing know One we in terms you the space, the forward ViiV in to on space; antivirals of working two that number and to importance. in expect are already objectives platform with over First our different

At field the same variety we time to continue on of which for inbound broad such a different applicability. uses requests technology, demonstrated has this

and internal our on between at XXXX line and forward doing what thing to we're fine as be the focusing a it's LNC immediately or platform to the but biotech, we of resources hand those most do is thinking demonstrate creation what placing maybe on those progressed making think next XXXX, programs announcements attention more can the how so. opportunities. in utilized few Sometimes on broadly, continuing value terms of to right additional certainly immediate We and then in look and year importance in focusing over forward and the quarters next

Robert Hazlett

And a sense. to do but announced regarding it's pretend thoughts. that Thanks, class? programs think And with difficult questions the -- just for for discussion anything this what really one. in your if determine last of would out that you specific out might that been come Obviously, one EnACT.com makes might what come of is that's that that I'm omega-X. competitor interested

Jerry Jabbour

something Sure. and anticipated And area. of specifically years that, the necessarily with the the let's that reality questions face but an to should of to been respect want probably that's CPA obviously think in I we certainly, is Ferguson time entire comment experience Dr. But have his because on here. not given outcome

which but not is FDA From position that to perspective, but of do potentially data it, think to follow place I've tens product data class. of their obligation evaluation about you treat that promise CPA just the an a an an have millions of the patients. products they how not now in With reduce only entire

should an we and market we forward perspective, that how for of our from and all may it's the been surprise. timing this the think certainly expected overall, caught class something and emerge have may to has look is so exactly investors should Dr. this the And let it I'll but have profile the patients is as how this affordable that for an set along, But notwithstanding believe as opportunity many class class, with certainly probably and up that do kind by has to with FDA that Ferguson patients, to comment cost for potential safety to it and the if we and a what really us. going treat

Terry Ferguson

Yes, building bit. on a little that

I it think that the -- the this the view in reduce data for robust. class is good are very my really because

the of data there. that's the mentioned, the All this It's lots the that proper at up clinical one time, of things endpoints and are. potentially to lots those Jerry impressive applicable line more are you and in it more is of patients the trial. an that look direction At amazing as same the out

that they're are and outcomes And -- questions who observed how be for to And the to broad that to at arise closer it's opportunity reparable the to -- are cardiovascular is data again, reduce stronger. others and the at of data, and elevated with it that in the reduction that look driving is to triglycerides. there just So reduce that population risk and it just I of behind, to going Omega-X for what high look stronger look it addressed that patients coming relates Omega-X, much be for just that comes the is it this I in And XXXX. reduce is it class that are why not fundamental and continues not simply big questions but take because the and the you population forward. much And the those the this a including as the people and it? the welcome just are CPA have was the as trial triglycerides who think

the about for optimistic I'm class. So this very

Robert Hazlett

forward more. the to Appreciate on color again progress. additional and Look congratulations the

Terry Ferguson

Thanks, Bert.

Operator

Thank next is Jason you coming our Maxim McCarthy today from question from Group.

now is live. line Your

Jason McCarthy

Jerry, want to questions. thanks shift I taking for back to the Hi, XXXX.

it's the adding on underserved, And in relative focus space at I think to in [ph] an do Amarin XXXX there's AstraZeneca. is much cryptococcal incredibly underserved which the space look antibiotic believe meningitis Omega-X and even to market you market. general? When how at you the oral an you look anti-fungal at Because I broad a HIV indication, kind and and look my ampho, XXXX a indication. in experience of so that's continue IV at to use us large particularly ampho when you available very but Can mile-high with drug a a community, as Africa any will small, is like And perspective on potentially tend toxicity, in for that? whatever oral know. absolutely around is no like fungal give builds doctors, you awareness

Jerry Jabbour

thanks question. turning the Jason the XXXX. Again, Sure. to And call thanks for for back

advancing what Peter demonstration more see stringent Health, his treatment could the probably with in you important But the been caused at some of areas of MAT the need beginning, has years longer by that mycologists us you're focus greatest in and be to focus fortunate things and We're I that's think has And Matinas you acid really additional benefit that that asset, X that Institutes single data, is as that Williamson's of surrounded for a that of opportunity. even the isn't the that us, from where on particularly from of makes leading a this threshold you're even this not Is to very a data and the unmet than investment. the work to unique to to it's model the been the started right with community. right medical lot world. a in done market We emerge, to last a And mouse one say prophylaxis. a small prophylaxis. this over are binary Company. National really And than omega-X become XXXX. on started certainly started

up in the our want population to the of patient model. and this why the largest to where the crypto how of high-risk the rate. sets essentially, so team made with those NIH with unfortunately, the combined because patient in population, Mannino plus the design an orphan combination that to in that's that combine presented mortality even dollars. own gets entire became product. Dr. and preclinical subjected greatest without commercial data acute you of funding models, the you And it support subjecting a this in in so and having the opportunity to platform sure use the a forward Yes, risk? fact the treatments, be that a you of NIH those study the opportunity time a cryptococcal meningitis indication protocol. then, the product you And for without the there's is Minnesota much subsequently financial Matkovits, it unnecessary and Dr. But not where the And interest on XX% It It is and do to and University U.S. spend population, a to patients way perfect demonstration, an great we move have

fungal upon the back can patients invasive with QIDP, we believe treat We aspergillosis. we in positions after already for and most in to of is that that invasive it's one a other need we've to treat can FDA. EnACT trial, to demonstration but a which the candidiasis go the effectively have the that the the So huge treatment in XXXBX advanced the safely demonstration drug this and that infections infections great been difficult of Matkovits our pathway operate and Dr. utilizing fungal alluded the invasive discussions these

are fungal in advances of immuno-compromised. those because the eventually, subjected immuno-compromised infections render risk invasive of yes, we believe additional in medicine, them patients And to prevention patients, who

of oral, across people there. advanced lack well-tolerated the the that get opportunity unmet amphotericin given indications. to where space the So this that opportunity, great brings, and board that need the see, in to And to the fit. investment us medical antifungal you is That's therapies that when that's and about those to XXXX use XXXX talked going the as Terry about, then a in safe, is MAT new billion-dollar-plus for bridge study think us MAT the point prove an the

Jason McCarthy

or whatever, And animal antifungal translate can or in you a weight. also, models therapy somebody it's just we're oncology that's humans. something or briefly, subject, talk that of Whether or or models? about different or this I and little nicely a your think, Id quite in antibiotic talk group use while into in about on it the typically Well, what bit high preclinical to you anti-infective? otherwise, doesn't to is In infectious or gene because lot hold tends triglycerides tends see disease, carry that's

think Can a carry I So models work? that to more the just address bit little that weight. somebody preclinical

Jerry Jabbour

like important Sure. Dr. think comment and really to a point Jason, it's we have so I'd Matkovits that. on

Theresa Matkovits

out you In have was animal world, MATXXXX the seen many borne The such current rigorous that's the ability standard models Yes, this anti-infective And IV IV that absolutely Health And in the Health. as what just test National raise is predictive behaved the in what the is care an us of of efficacy. mouse demonstrate the in model studies replication excellent our Institute been and with amphotericin. point. to good of at highly that instrumental there that National clinical validation Peter antifungal clinically. does not are better the that's and as by least animal of the done than was funding clinically if trial for because Dr. of that in was effective, decision basis driving really Institutes been for the the hands, amphotericin investment used key it model In Williamson's to that was alone MATXXXX. really in by

Jerry Jabbour

add Jason, thing. just to more And one that just on

that platform in is with animal to I with think over that on really we reality seen reality models, ability this specifically the the is you've The well. and that predictive toxicity. unfortunate is respect And seen development few efficacy solve. medicines. safety. anti-infective centered exactly of is space this translates anti-infective That failures the our of platform challenge other are to last They're really, reality our the the years of on designed have centered the

the is and the can that So we're predictive bringing ability we bear fact nature in to on demonstrated the rely of the patient safety. models, we preclinical about efficacy solution like the our

combination, up So think for outcome a we very this good be sets study XXXX. to potential that MAT

Jason McCarthy

in be any resistance screening real part next data -- or samples just azole will quick, Okay, for patient will of set? you the you your resistance other as

Theresa Matkovits

have we included the currently, protocol. in not So that

open However, future we've adaptations. left protocol the to

So in can progresses. fashion an look that we as study something that for is the exploratory

Jason McCarthy

for great. the questions. taking Okay, Thanks

Jerry Jabbour

Jason. Thanks,

Operator

from coming [Operator Instructions] from Our question next Company. Needham & is Messer Chad

Your is live. line now

Chad Messer

and morning But your important question. profile understood little little DPA It taking seems a is differentiating understood thanks than DHA. it's like with less is an state DPA that's it inclusion to or seems working knowledge Can the and on improve about about of knowledge collaborators? of some contribution is Good what how steps you going the whether MATXXXX maybe Great. comment its sort for or less and working of of for efficacy to are EPA DPA. it's is amount our of of my what part how academic at sort a on current there proprietary and Matinas

Jerry Jabbour

Great.

some position. we and color the hallmark of at And Chad, for on Dr. MATXXXX ask why certainly, then, perhaps Ferguson is comment can assume add thanks, a the I'll think end. best-in-class key it, Now differentiation question. the potential to

Terry Ferguson

basic kind on additional different of in is of is reduce DHA triglycerides actually a out a potent variety drugs, and of genetic are least ways potent it's of is triglyceride-lowering clear for omega-Xs drugs. to PCSKX how these currently markers, effects in relating of membranes, the DPA there also of all same, kid-on-the-block. in Yes, triglyceride-lowering lot the of one and is them, science that think lot a the being to, different omega-Xs have the instance, omega-Xs hierarchy to discussions that a middle, new work what the incorporated the so the in the lot has for and turns be DPA I They past done into of EPA -- and do and most the basic we're they a There there the membrane this. been are to the of clear ability of fluidity, that of work not is the

the circumstances. we basic in DHA fit omega-Xs looking DPA done advance there additional a to understanding and and same So into of with the be we are has where this, going science sort been work are also to those EPA work of exactly scenes supporting behind lot of continuing the at

Chad Messer

Great, work. thanks. the to hear important good It's this is that behind science

Jerry Jabbour

question. for the Absolutely, Chad. Thanks

Operator

you. Thank

We Ladies conclude closing of that our back today's have does comments. floor any I'd and to reached teleconference. session. the or this gentlemen, further At like end point, question-and-answer Jerry for the to turn

Jerry Jabbour

a effective both, time this, and follower to we a period you very a have the activity. science-driven play, patients. interest to can Matinas. we're isn't that things and this At end thank different assembled commence of which data a of demonstrations very day, us at become be we Obviously, -- MATXXXX show starting of asset about significant is this Great, be do the are MATXXXX to to business, BioPharma. all products able doing forward, day, proud XX the next a here be Matinas months positioning solutions studies we exciting team have appreciate We rules of why That's the in should we for the driving are the XX single much. these are to everyone's and

your you look forward Thank to months. the and Enjoy you over time summer, the for of today. coming update rest to continuing we

Operator

conclude and today's That does you. Thank webcast. teleconference

a your You today. this We time, may at thank you your disconnect wonderful day. and lines participation have for

Matinas BioPharma (MTNB) 13 Aug 192019 Q2 Earnings call transcript